Institutional shares held 192 Million
1.71M calls
865K puts
Total value of holdings $2.8B
$24.9M calls
$12.6M puts
Market Cap $3.71B
254,330,000 Shares Out.
Institutional ownership 75.43%
# of Institutions 793


Latest Institutional Activity in OGN

Top Purchases

Q3 2024
Weiss Asset Management LP Shares Held: 1.72M ($25.1M)
Q3 2024
Citadel Advisors LLC Shares Held: 2.88M ($42.1M)
Q3 2024
Deprince Race & Zollo Inc Shares Held: 4.42M ($64.5M)
Q3 2024
Jacobs Levy Equity Management, Inc Shares Held: 1.24M ($18.1M)
Q3 2024
Lsv Asset Management Shares Held: 7.49M ($109M)

Top Sells

Q3 2024
Slate Path Capital LP Shares Held: 2.46M ($35.9M)
Q3 2024
Principal Financial Group Inc Shares Held: 1.22M ($17.7M)
Q3 2024
Aqr Capital Management LLC Shares Held: 2.47M ($36.1M)
Q3 2024
Invesco Ltd. Shares Held: 1.41M ($20.5M)
Q3 2024
Nordea Investment Management Ab Shares Held: 6.74M ($98.3M)

About OGN

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.


Insider Transactions at OGN

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
478K Shares
From 19 Insiders
Exercise of conversion of derivative security 415K shares
Grant, award, or other acquisition 60.5K shares
Open market or private purchase 2.72K shares
Sell / Disposition
200K Shares
From 10 Insiders
Payment of exercise price or tax liability 200K shares

Track Institutional and Insider Activities on OGN

Follow Organon & Co. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells OGN shares.

Notify only if

Insider Trading

Get notified when an Organon & Co. insider buys or sells OGN shares.

Notify only if

News

Receive news related to Organon & Co.

Track Activities on OGN